AFFY  Affymax Inc.

Exchange

NASDAQ

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

3.7M

Current Price

$0.10
-0.0005 (-0.50%)

Book Price

$-0.28
Overvalued by 375.49%
Financial Institution

Company Metrics

  • 0.34 P/E
  • 7.18 P/S
  • 103.33 P/B
  • 0.3 EPS
  • 0 / 0% Dividend
  • 503,146.00 Avg. Vol.
  • 37.00M Shares
  • 3.7M Market Cap.

Company Description

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Affymax board decides to dissolve company
NephrologyNews.com - Jul 1, 2014
Affymax Inc. announced that its board of directors has approved the liquidation and dissolution of the company, subject to stockholder approval, and plans to distribute all available cash to its stockholders as soon as legally permitted and reasonably ...
Affymax Shares are Trading near Liquidation Value; Analyst Report by ...
Wall Street Journal - Jun 30, 2014
Affymax, Inc. (OTCQB: AFFY) is a biopharmaceutical company that was formed to discover, develop and deliver innovative therapies for patients with serious diseases, including kidney disease.
Puma Biotechnology: Another Jackpot For Investors
Forbes - Jul 23, 2014
Investors who purchased shares in Puma Biotechnology Puma Biotechnology Inc. before the closing of Wall Street on Tuesday—at around $60 or better at the 52-week low of $33.70 - hit the jackpot.
Glaxos Label Expansion Plans Marred as Arzerra Disappoints
Zacks.com - Jun 30, 2014
Some better-ranked stocks in the health care sector include Allergan (AGN - Analyst Report), Regeneron Pharmaceuticals, Inc. (REGN - Analyst Report) and Affymax, Inc. . While Regeneron carries a Zacks Rank #1 (Strong Buy), Allergan and Affymax hold a ...
Glaxo's Label Expansion Plans Marred as Arzerra Disappoints - Analyst Blog - NASDAQ
Acthar's Future Could Be An Adverse Event For Mallinckrodt
Seeking Alpha - Jul 17, 2014
While the latter would be a rare step, recall that Omontys, a drug marketed by Affymax (NASDAQ:AFFY) and Takeda Pharmaceutical (4502.
Affymax board announces decision to dissolve the company
Reuters Key Development - Jun 24, 2014